I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway

Human Molecular Genetics

Volumn 24, Issue 17, 2015, Pages 4879-4900

  Ohta, Etsuro ^a,b   Nihira, Tomoko ^a,b   Uchino, Akiko ^a,c   Imaizumi, Yoichi ^b   Okada, Yohei ^b,d   Akamatsu, Wado ^b,e   Takahashi, Kayoko ^f   Hayakawa, Hideki ^a   Nagai, Makiko ^g   Ohyama, Manabu ^b   Ryo, Masafuchi ^g   Ogino, Mieko ^g   Murayama, Shigeo ^c   Takashima, Akihiko ^h   Nishiyama, Kazutoshi ^a,g   Mizuno, Yoshikuni ^a   Mochizuki, Hideki ⁱ   Obata, Fumiya ^a   Okano, Hideyuki ^b  

^a KITASATO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KITASATO UNIVERSITY HOSPITAL   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

ⁱ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE RICH REPEAT KINASE 2; PROTEIN KINASE B; TAU PROTEIN; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; APOPTOSIS; ARTICLE; AUTOPHAGY; CASE REPORT; CELL DIFFERENTIATION; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE (PEOPLE); NERVE CELL; NERVE DEGENERATION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; ANIMAL; CELL LINE; CYTOLOGY; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; MUTATION; PHOSPHORYLATION; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AUTOPHAGY; CASPASE 3; CELL LINE; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MUTATION; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84941886639     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv212     Document Type: Article

References (62)

1. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
2. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks,W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
3. Funayama, M., Hasegawa, K., Ohta, E., Kawashima, N., Komiyama, M., Kowa, H., Tsuji, S. and Obata, F. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol., 57, 918-921.
4. Gasser, T. (2009) Mendelian forms of Parkinson's disease. Biochim Biophys Acta., 1792, 587-596.
5. Corti, O., Lesage, S. and Brice, A. (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev., 91, 1161-1218.
6. Bardien, S., Lesage, S., Brice, A. and Carr, J. (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. Parkinsonism Relat. Disord., 17, 501-508.
7. Meylan, E. and Tschopp, J. (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci., 30, 151-159.
8. Lobbestael, E., Baekelandt, V. and Taymans, J.M. (2012) Phosphorylation of LRRK2: from kinase to substrate. Biochem. Soc. Trans., 40, 1102-1110.
9. Imai, Y., Gehrke, S.,Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
10. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of howParkinson's disease mutants affect kinase activity. Biochem. J., 405, 307-317.
11. Kawakami, F., Yabata, T., Ohta, E., Maekawa, T., Shimada, N., Suzuki, M., Maruyama, H., Ichikawa, T. and Obata, F. (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One, 7, e30834.
12. Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.C., Jia, H., Stankowski, J., Kim, M.S., Zhong, J., Kumar, M. et al. (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell, 157, 472-485.
13. Smith,W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
14. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 16, 223-232.
15. Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T., Kolch,W., Prokisch, H. and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 15, 223-232.
16. Luzon-Toro, B., de la Torre, E.R., Delgado, A., Perez-Tur, J. and Hilfiker, S. (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet., 16, 2031-2039.
17. Anand, V.S., Reichling, L.J., Lipinski, K., Stochaj,W., Duan,W., Kelleher, K., Pungaliya, P., Brown, E.L., Reinhart, P.H., Somberg, R. et al. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J., 276, 466-478.
18. Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro, 1, e00002.
19. Ohta, E., Kawakami, F., Kubo, M. and Obata, F. (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett., 585, 2165-2170.
20. Ohta, E., Kawakami, F., Kubo, M. and Obata, F. (2013) Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation. Biochem. Biophys. Res. Commun., 430, 560-566.
21. Plowey, E.D., Cherra, S.J. 3rd, Liu, Y.J. and Chu, C.T. (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem., 105, 1048-1056.
22. Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R.E., Langston, W. et al. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 8, 267-280.
23. Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J.R., Carrillo-Reid, L., Xie, Z., Osborn, T. et al. (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med., 4, 141ra90.
24. Reinhardt, P., Schmid, B., Burbulla, L.F., Schöndorf, D.C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, S.A., Dhingra, A. et al. (2013) Genetic correction of a LRRK2 mutation in human iPSC links parkinsonian neurodegeneration to ERKdependent changes in gene expression. Cell Stem Cell, 12, 354-367.
25. Sánchez-Danés, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jiménez-Delgado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A. et al. (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med., 4, 380-395.
26. Liu, G.H., Qu, J., Suzuki, K., Nivet, E., Li, M., Montserrat, N., Yi, F., Xu, X., Ruiz, S., Zhang,W. et al. (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature, 491, 603-607.
27. Sanders, L.H., Laganière, J., Cooper, O., Mak, S.K., Vu, B.J., Huang, Y.A., Paschon, D.E., Vangipuram, M., Sundararajan, R., Urnov, F.D. et al. (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol. Dis., 62, 381-386.
28. Imaizumi, Y., Okada, Y., Akamatsu,W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S. et al. (2012) Mitochondrial dysfunction associated with increased oxidative stress and a-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain, 5, 35.
29. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
30. Ujiie, S., Hatano, T., Kubo, S., Imai, S., Sato, S., Uchihara, T., Yagishita, S., Hasegawa, K., Kowa, H., Sakai, F. et al. (2012) LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat. Disord., 18, 819-823.
31. Hasegawa, K., Stoessl, A.J., Yokoyama, T., Kowa, H., Wszolek, Z.K. and Yagishita, S. (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord., 15, 300-306.
32. Attems, J., Thal, D.R. and Jellinger, K.A. (2012) The relationship between subcortical tau pathology and Alzheimer's disease. Biochem. Soc. Trans., 40, 711-715.
33. Ohta, E., Katayama, Y., Kawakami, F., Yamamoto, M., Tajima, K., Maekawa, T., Iida, N., Hattori, S. and Obata, F. (2009) I2020T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem. Biophys. Res. Commun., 390, 710-715.
34. Ohta, E., Kubo, M. and Obata, F. (2010) Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Biochem. Biophys. Res. Commun., 391, 242-247.
35. Greene, I.D., Mastaglia, F., Meloni, B.P., West, K.A., Chieng, J., Mitchell, C.J., Gai,W.P. and Boulos, S. (2014) Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation. J. Neurosci. Res., 92, 506-516.
36. Dudek, H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R. and Greenberg, M.E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 275, 661-665.
37. Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
38. Milosevic, J., Schwarz, S.C., Ogunlade, V., Meyer, A.K., Storch, A. and Schwarz, J. (2009) Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol. Neurodegener., 4, 25.
39. Shin, N., Jeong, H.,Kwon, J., Heo, H.Y.,Kwon, J.J., Yun, H.J., Kim, C.H., Han, B.S., Tong, Y., Shen, J. et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res., 314, 2055-2065.
40. Piccoli, G., Condliffe, S.B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., Meixner, A., Sarioglu, H., Vogt-Weisenhorn, D.M., Wurst,W. et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 31, 2225-2237.
41. Belluzzi, E., Greggio, E. and Piccoli, G. (2012) Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. Biochem. Soc. Trans., 40, 1111-1116.
42. Migheli, R., Del Giudice, M.G., Spissu, Y., Sanna, G., Xiong, Y., Dawson, T.M., Dawson, V.L., Galioto, M., Rocchitta, G., Biosa, A. et al. (2013) LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS One, 8, e77198.
43. Yun, H.J., Park, J., Ho, D.H., Kim, H., Kim, C.H., Oh, H., Ga, I., Seo, H., Chang, S., Son, I. et al. (2013) LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp. Mol. Med., 45, e36.
44. Pan, P.Y., Tian, J.H. and Sheng, Z.H. (2009) Snapin facilitates the synchronization of synaptic vesicle fusion. Neuron, 61, 412-424.
45. Cheng, K.K., Lam, K.S., Wu, D.,Wang, Y., Sweeney, G., Hoo, R. L., Zhang, J. and Xu, A. (2012) APPL1 potentiates insulin secretion in pancreatic ß cells by enhancing protein kinase Aktdependent expression of SNARE proteins in mice. Proc. Natl. Acad. Sci. USA, 109, 8919-8924.
46. Rojo, L., Sjöberg, M.K., Hernández, P, Zambrano, C. and Maccioni, R.B. (2006) Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J. Biomed Biotechnol., 2006, 73976.
47. Medina, M. and Wandosell, F. (2011) Deconstructing GSK-3: The Fine Regulation of Its Activity. Int. J. Alzheimers Dis., 2011, 479249.
48. Cohen, P. and Frame, S. (2001) The renaissance of GSK3. Nat. Rev. Mol. Cell Biol., 2, 769-776.
49. Lin, C.H., Tsai, P.I., Wu, R.M. and Chien, C.T. (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK-3ß. J. Neurosci., 30, 13138-13149.
50. Kawakami, F., Shimada, N., Ohta, E., Kagiya, G., Kawashima, R., Maekawa, T., Maruyama, H. and Ichikawa, T. (2014) Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3ß. FEBS J., 281, 3-13.
51. Cookson, M.R., Hardy, J. and Lewis, P.A. (2008) Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol., 1, 217-231.
52. Jenner, P. (2003) Oxidative Stress in Parkinson's disease. Ann. Neurol., 53, S26-S38.
53. Ohta, S., Imaizumi, Y., Okada, Y., Akamatsu, W., Kuwahara, R., Ohyama, M., Amagai, M., Matsuzaki, Y., Yamanaka, S., Okano, H. et al. (2011) Generation of human melanocytes from induced pluripotent stem cells. PLoS One, 6, e16182.
54. Yagi, T., Kosakai, A., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Nabetani, A., Ishikawa, F., Arai, Y., Hirose, N., Okano, H. and Suzuki, N. (2012) Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One, 7, e41572.
55. Okada, Y., Matsumoto, A., Shimazaki, T., Enoki, R., Koizumi, A., Ishii, S., Itoyama, Y., Sobue, G. and Okano, H. (2008) Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/ progenitor cells. Stem Cells, 26, 3086-3098.
56. Higurashi, N., Uchida, T., Lossin, C., Misumi, Y., Okada, Y., Akamatsu, W., Imaizumi, Y., Zhang, B., Nabeshima, K., Mori, M.X. et al. (2013) A human Dravet syndrome model from patient induced pluripotent stem cells. Mol. Brain, 6, 19.
57. Nori, S., Okada, Y., Yasuda, A., Tsuji, O., Takahashi, Y., Kobayashi, Y., Fujiyoshi, K., Koike, M., Uchiyama, Y., Ikeda, E. et al. (2011) Grafted human induced pluripotent stem cell--derived neurospheres promotes motor functional recovery after spinal cord injury in mice. Proc. Natl. Acad. Sci. USA, 108, 16825-16830.
58. Ohta, E., Hasegawa, K., Gasser, T. and Obata, F. (2007) Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. Neurosci. Lett., 417, 21-23.
59. Yamamori, S., Itakura, M., Sugaya, D., Katsumata, O., Sakagami, H. and Takahashi, M. (2011) Differential expression of SNAP-25 family proteins in the mouse brain. J. Comp. Neurol., 519, 916-932.
60. Kataoka, M., Yamamori, S., Suzuki, E., Watanabe, S., Sato, T., Miyaoka, H., Azuma, S., Ikegami, S., Kuwahara, R., Suzuki-Migishima, R. et al. (2011) A single amino acid mutation in SNAP-25 induces anxiety-related behavior in mouse. PLoS One, 6, e25158.
61. Ohnishi, H., Yamamori, S., Ono, K., Aoyagi, K., Kondo, S. and Takahashi, M. (2001) A src family tyrosine kinase inhibits neurotransmitter release from neuronal cells. Proc. Natl. Acad. Sci. USA, 98, 10930-10935.
62. Nishiki, T., Shoji-Kasai, Y., Sekiguchi, M., Iwasaki, S., Kumakura, K. and Takahashi, M. (1997) Comparison of exocytotic mechanisms between acetylcholine- and catecholaminecontaining vesicles in rat pheochromocytoma cells. Biochem. Biophys. Res. Commun., 239, 57-62.